Obinutuzumab beta (Bejescin)
Monoclonal antibody
Evidence outlook
Approved: Neuromyelitis optica spectrum disorder (Bejescin, obinutuzumab beta) (CN)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Latest reported trial: NCT05862233 · Phase 3 · met primary endpoint · grade pending
Also in development:Systemic Lupus Erythematosus · Phase 3 · investigational in the USFollicular Lymphoma · Phase 3 · investigational in the US
Also approved (1)
- Neuromyelitis optica spectrum disorder (Bejescin, obinutuzumab beta)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05862233 NCT05862233 · Primary Membranous Nephropathy Registry: NCT05862233 | 3 | Complete remission rate at Week 76 2025-05-13 | Primary endpoint, complete remission at week 76: 49.4% with MIL62 (n=77) vs 3.9% with cyclosporine A (n=76); difference 46.5% (95% CI 32.1 to 60.9), P<0.0001 (Cui Z et al., J Am Soc Nephrol 2025;36(10S)). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other CD20 drugs
Obinutuzumab, Ocrelizumab, Ocrevus Zunovo, Ofatumumab, PF-05280586 and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, 8 of them ahead of this one.
This drug's own stage for Follicular Lymphoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Obinutuzumab Beta (Bejescin): this drug | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ocrelizumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | Reliable signal | NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab-Abbs (Truxima) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Reliable signal | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| ABP 692 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Acellbia | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HLX01 (Hanlikang) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Obinutuzumab beta (Bejescin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent